Single Peptides · Exact presentation
Retatrutide · 20 mg Vial
Retatrutide · 20 mg Vial is an exact single peptide or compound entry. This strength is kept separate because concentration and calculations depend on vial amount.
Educational research information for this exact variation. It is not medical advice, a prescription, or proof of regulatory approval.
Separate commercial record
Availability in the Dominican Republic
This educational entry is separate from the live catalog. Check the exact commercial record for current availability, price, and lot documentation. View exact commercial record.
Dosing & Reconstitution Guide
For a 20 mg presentation, the reference concentration of 10 mg/mL mathematically corresponds to 2 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 10 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.1 mg at this concentration.
Standard / Gradual Approach (2 mL = ~10.0 mg/mL)
The source chart summarizes “2 mg–8 mg” at “Weekly” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Standard / Gradual Approach (2 mL = ~10.0 mg/mL)
| Phase | Weekly Dose | Units (per injection) (mL) | Vials Needed |
|---|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) | 1 vial per dose |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) | 1 vial per dose |
| Weeks 9–12 | 6 mg (6000 mcg) | 60 units (0.60 mL) | 1 vial per dose |
| Weeks 13+ | 8 mg (8000 mcg) | 80 units (0.80 mL) | 1 vial per dose |
Reconstitution Steps
For a 20 mg presentation, the reference concentration of 10 mg/mL mathematically corresponds to 2 mL final volume. This is concentration math, not a universal preparation instruction; the lot CoA and documentation control. 10 mg/mL. On a U-100 syringe, 1 unit equals 0.01 mL; the amount per unit would be 0.1 mg at this concentration.
Advanced / Aggressive Protocol (2 mL = ~10.0 mg/mL)
The source chart summarizes “2 mg–8 mg” at “Weekly” frequency as educational information. PeptidosRD does not convert it into a clinical recommendation; any protocol must be checked against primary studies, applicable labeling, and qualified oversight.
Advanced / Aggressive Protocol (2 mL = ~10.0 mg/mL)
| Phase | Weekly Dose | Units (per injection) (mL) | Vials Needed |
|---|---|---|---|
| Weeks 1–4 | 2 mg (2000 mcg) | 20 units (0.20 mL) | 1 vial per dose |
| Weeks 5–8 | 4 mg (4000 mcg) | 40 units (0.40 mL) | 1 vial per dose |
| Weeks 9–12 | 8 mg (8000 mcg) | 80 units (0.80 mL) | 1 vial per dose |
| Weeks 13+ | 12 mg (12000 mcg) | 120 units (1.20 mL) | 1 vial per dose |
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.[5]
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.[6]
Allow vials to reach room temperature before opening to reduce condensation uptake.
How This Works
It is studied for metabolic signaling involving incretin receptors and, depending on the compound, amylin or glucagon. Activity differs across single, dual, and triple agonists.
Clinical Benefits & Side Effects
Class-related considerations include gastrointestinal effects, measurement errors, and risks from unapproved products. A research vial is not automatically equivalent to an authorized medicine.
Benefits
Evidence strength varies: some active ingredients have human trials and specific authorized uses, while others remain in clinical or preclinical development.
Source trail
Scientific references and source discovery
- PeptideDosages — exact Retatrutide · 20 mg Vial entrysecondary-structure
- PubMed — literature search for Retatrutideprimary-discovery
- ClinicalTrials.gov — study search for Retatrutidetrial-registry
- Phase 2 obesity trial — PubMed 37366315primary
- Phase 2 type 2 diabetes trial — PubMed 37385280primary
- Discovery and proof of concept — PubMed 35985340primary
- Trial record NCT04881760trial-registry
- FDA — concerns with unapproved GLP-1 productsregulatory
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference
- View Sourcesource-reference